Literature DB >> 16769787

Mycophenolate mofetil for lupus related myelopathy.

C C Mok, A Mak, C H To.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16769787      PMCID： PMC1798209          DOI： 10.1136/ard.2005.046615

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Mycophenolate-mofetil in the treatment of refractory multiple sclerosis.

Authors:  N Ahrens; A Salama; J Haas
Journal:  J Neurol       Date:  2001-08       Impact factor: 4.849

2.  Sequential therapies for proliferative lupus nephritis.

Authors:  Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

3.  Transverse myelitis in systemic lupus erythematosus--the effect of IV pulse methylprednisolone and cyclophosphamide.

Authors:  L Barile; C Lavalle
Journal:  J Rheumatol       Date:  1992-03       Impact factor: 4.666

4.  Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy.

Authors:  C C Mok; C S Lau; R W Wong
Journal:  Arthritis Rheum       Date:  1998-05

5.  Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.

Authors:  Tak-Mao Chan; Kai-Chung Tse; Colin Siu-On Tang; Mo-Yin Mok; Fu-Keung Li
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

6.  Improving the sensitivity of the Barthel Index for stroke rehabilitation.

Authors:  S Shah; F Vanclay; B Cooper
Journal:  J Clin Epidemiol       Date:  1989       Impact factor: 6.437

7.  Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome.

Authors:  C C Mok; C S Lau; E Y Chan; R W Wong
Journal:  J Rheumatol       Date:  1998-03       Impact factor: 4.666

8.  Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients.

Authors:  Cecilia N Pisoni; Francisco J Sanchez; Yousuf Karim; Maria J Cuadrado; David P D'Cruz; Ian C Abbs; Munther A Khamasta; Graham R V Hughes
Journal:  J Rheumatol       Date:  2005-06       Impact factor: 4.666

9.  Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

10.  Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus.

Authors:  C M Neuwelt; S Lacks; B R Kaye; J B Ellman; D G Borenstein
Journal:  Am J Med       Date:  1995-01       Impact factor: 4.965
  10 in total
  3 in total

Review 1.  Mycophenolate mofetil in the treatment of systemic lupus erythematosus.

Authors:  Ali Sahin
Journal:  Eurasian J Med       Date:  2009-12

2.  Suspected Transverse Myelitis with Normal MRI and CSF Findings in a Patient with Lupus: What to Do? A Case Series and Systematic Review.

Authors:  Rory C Monahan; Hannelore J L Beaart; Rolf Fronczek; Gisela M Terwindt; Liesbeth J J Beaart-van de Voorde; Jeroen de Bresser; Margreet Kloppenburg; Nic J A van der Wee; Tom W J Huizinga; Gerda M Steup-Beekman
Journal:  Neuropsychiatr Dis Treat       Date:  2020-12-22       Impact factor: 2.570

Review 3.  Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives.

Authors:  César Magro-Checa; Elisabeth J Zirkzee; Tom W Huizinga; Gerda M Steup-Beekman
Journal:  Drugs       Date:  2016-03       Impact factor: 9.546
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.